NCT03564691 2025-10-07
MK-4830-001
Merck Sharp & Dohme LLC
Phase 1 Completed
Clinical Trials
12 trialsNCT02640508 2024-05-09
Eribulin and Lenvatinib in Advanced Solid Tumors
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT02501096 2023-07-20
A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors
Eisai Inc.
Phase 1/2 Completed
NCT02432274 2023-07-11
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
Eisai Inc.
Phase 1/2 Completed
NCT00121719 2023-06-22
An Open Label Dose Escalation Study Of E7080
Eisai Inc.
Phase 1 Completed
NCT01268293 2023-06-22
A Study of E7080 in Subjects With Solid Tumor
Eisai Inc.
Phase 1 Completed
NCT01761266 2022-04-05
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
Eisai Inc.
Phase 3 Completed
NCT04008082 2022-03-08
A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma
Eisai Inc.
Completed
NCT02686164 2019-08-28
Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors
Eisai Inc.
Phase 1 Completed
NCT00280397 2016-10-07
An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors
Eisai Inc.
Phase 1 Completed
NCT00121680 2015-12-11
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma
Eisai Inc.
Phase 1 Completed
NCT01240408 2015-03-04
E7080 Food Effect Study in Healthy Subjects
Eisai Inc.
Phase 1 Completed